CN115379830A - 固体药物制剂及其制备方法和用途 - Google Patents

固体药物制剂及其制备方法和用途 Download PDF

Info

Publication number
CN115379830A
CN115379830A CN202180027685.7A CN202180027685A CN115379830A CN 115379830 A CN115379830 A CN 115379830A CN 202180027685 A CN202180027685 A CN 202180027685A CN 115379830 A CN115379830 A CN 115379830A
Authority
CN
China
Prior art keywords
active ingredient
solid pharmaceutical
particle size
pharmaceutical formulation
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027685.7A
Other languages
English (en)
Inventor
江涛涛
王吉标
杨菡
李利
但招陵
朱科屹
曾振亚
苏波
陈曦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Original Assignee
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yangtze River Pharmaceutical Group Co Ltd, Shanghai Haiyan Pharmaceutical Technology Co Ltd filed Critical Yangtze River Pharmaceutical Group Co Ltd
Publication of CN115379830A publication Critical patent/CN115379830A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Abstract

本发明涉及一种固体药物制剂及其制备方法，具体地，公开了一种包含食欲素受体拮抗剂化合物的固体药物制剂及其制备方法，所述固体药物制剂包含活性成分式I化合物、填充剂、粘合剂、崩解剂、润滑剂。该固体药物制剂具有良好的溶出度、稳定性以及体内生物利用度。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN202180027685.7A 2020-04-17 2021-04-14 固体药物制剂及其制备方法和用途 Pending CN115379830A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010304917 2020-04-17
CN2020103049176 2020-04-17
CN202011594757 2020-12-29
CN202011594757X 2020-12-29
PCT/CN2021/087262 WO2021208976A1 (zh) 2020-04-17 2021-04-14 固体药物制剂及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN115379830A true CN115379830A (zh) 2022-11-22

Family

ID=78084005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027685.7A Pending CN115379830A (zh) 2020-04-17 2021-04-14 固体药物制剂及其制备方法和用途

Country Status (8)

Country Link
US (1) US20230149402A1 (zh)
EP (1) EP4137124A4 (zh)
JP (1) JP7478839B2 (zh)
KR (1) KR20220145876A (zh)
CN (1) CN115379830A (zh)
AU (1) AU2021256788A1 (zh)
CA (1) CA3174409A1 (zh)
WO (1) WO2021208976A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114344306B (zh) * 2022-01-24 2023-09-26 苏州旺山旺水生物医药有限公司 含苯基嘧啶酮盐酸盐的药物组合物，包含其的药物制剂，及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090031618A (ko) 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
TW201444849A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
CA2941663C (en) * 2014-03-06 2020-02-18 Shanghai Haiyan Pharmaceutical Technology Co. Ltd Piperidine derivatives as orexin receptor antagonist
JP6772251B2 (ja) 2015-08-14 2020-10-21 シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． オレキシン受容体拮抗薬の化合物の結晶形およびその製造方法と使用

Also Published As

Publication number Publication date
JP2023521192A (ja) 2023-05-23
US20230149402A1 (en) 2023-05-18
EP4137124A4 (en) 2024-05-15
AU2021256788A1 (en) 2022-11-24
EP4137124A1 (en) 2023-02-22
WO2021208976A1 (zh) 2021-10-21
JP7478839B2 (ja) 2024-05-07
CA3174409A1 (en) 2021-10-21
KR20220145876A (ko) 2022-10-31

Similar Documents

Publication Publication Date Title
TWI516477B (zh) Ｃ－ｍｅｔ調節劑醫藥組合物
US8227463B2 (en) Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same
KR102123130B1 (ko) 오렉신 수용체 길항제의 고체 투여 제제
US10098843B2 (en) Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
IL263978A (en) Amorphous has an amorphous formulation and solid pharmaceutical preparations that contain it and its uses
KR20180104125A (ko) 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물
TW202034903A (zh) 用於口服投予之包含胺基嘧啶衍生物或其鹽的醫藥組成物
CN115379830A (zh) 固体药物制剂及其制备方法和用途
CN105801568A (zh) 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
US20220226249A1 (en) Solid tablet dosage form of ridinilazole
RU2809722C1 (ru) Твердый фармацевтический препарат, способ его получения и применение
JP2023551056A (ja) 固体分散体、医薬製剤、その製造方法及び応用
CN113490492A (zh) 吡唑酰胺化合物的非晶质固体分散体
CN105228986B (zh) 一种氯卡色林共晶及其制备方法、药物组合物和用途
KR20230152118A (ko) 약물 조성물 및 이의 제조 방법 및 용도
WO2021145373A1 (ja) レンボレキサントの原薬及びそれを含有する医薬組成物
KR101741414B1 (ko) 크리소스플레놀 c 함유 고체 분산체, 이를 포함하는 약제학적 조성물 및 이의 제조방법
CN107648237B (zh) 氨基嘧啶类化合物的药物组合物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40075951

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination